Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.33 |
| ▸ | MTOR | P42345 | 3/20 | 0.33 |
| ▸ | PDE8B | O95263 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 3/20 | 0.32 |
| ▸ | GSK3B | P49841 | 3/20 | 0.32 |
| ▸ | TDP2 | O95551 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | DAO | P14920 | 1/20 | 0.30 |
| ▸ | GFER | P55789 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18037592 | 0.89 | GAA (0.39) | GAALMNA | |
| SCHEMBL31387261 | 0.86 | — | — | |
| SCHEMBL30784984 | 0.75 | PIK3CA (0.39) | PIK3CAMTORPDE8BTDP2 | |
| SCHEMBL19127856 | 0.74 | HTR1D (0.39) | GAA | |
| SCHEMBL18037528 | 0.70 | L3MBTL1 (0.39) | GAALMNAPDE8B | |
| SCHEMBL22572979 | 0.69 | AOC3 (0.39) | GAAPIK3CAPDE8BDAO | |
| SCHEMBL25036642 | 0.68 | CHIT1 (0.33) | GAAGFER | |
| SCHEMBL2945106 | 0.67 | PDE8B (0.35) | PIK3CAMTORPDE8BTDP2 | |
| SCHEMBL4016705 | 0.64 | DAO (0.47) | GSK3AGSK3BDAO | |
| SCHEMBL1988296 | 0.64 | KDM5B (0.37) | PIK3CAPDE8BDAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160251341-A1 | SUBSTITUTED TRIAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS | VERSEON INTERNATIONAL CORPORATION | 2016-09-01 | — | — | US | disclosed |
| WO-2013049591-A2 | DUAL INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | VERSEON CORPORATION (US) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251341-A1 | SUBSTITUTED TRIAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS | SPINT2, SERPINB1, PRSS1 | GAA 727/4885LMNA 1122/4885PIK3CA 1191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.